Due to variability in prostate screening access, comparison of incidence rates of prostate cancer is complex (prostate-specific antigen testing was introduced to Australia in the mid-1990s, without standardized screening criteria or programmes). This evidence concerns the gene KLK3 and prostate carcinoma.